Money
Filter News
Found 66,063 articles
-
Seattle startup AltPep targets amyloid deposits to treat Alzheimer's Disease.
-
Thermo Fisher Scientific announced the completion of Henogen SA, Groupe Novasep SAS’s viral vector manufacturing business in Belgium. The deal was for €725 million in cash.
-
Biopharma companies raking in the cash with investment rounds and IPO announcements.
-
VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLCAgreement extends current cash runway to Q1 2023
1/15/2021
VBL Therapeutics (Nasdaq: VBLT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications, today announced that it has entered into an Ordinary Share Purchase Agreement with Aspire Capital Fund, LLC. Proceeds from any sales of ordinary shares pursuant to the Purchase Agreement will be used for workin
-
Lilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund
1/15/2021
Fund will provide support for minority-owned early-stage healthcare companies and is a component of Lilly's racial justice efforts
-
Here’s a look at some of the stories that emerged from the conference on Wednesday.
-
Many buyers are becoming increasingly interested in buying these promising companies before they go public, as this often makes the purchase more economically feasible.
-
In many regards, the incoming Biden Administration is expected to be a redux of the Obama Administration, likely with strong support for scientific research and a reinvigoration of the Affordable Care Act. Yet concerns of pricing controls still loom.
-
Koya Medical Closes $11MM Financing to Accelerate Treatment for Lymphedema and Venous Disorders
1/14/2021
Koya Medical ( www.koyamedical.com ), a healthcare company focused on treating lymphedema and vein disease, today announced the close of a $11 million Series A investment round. The new investment was led by Arboretum Ventures. Jan Garfinkle , founder and managing director of Arboretum Ventures will join the board of directors
-
The Rockefeller Foundation launches $30M Advance Market Commitment with Thermo Fisher Scientific to Ramp up Procurement and Distribution of Covid-19 Testing
1/14/2021
As America's vaccination efforts get off to a slower than anticipated start, The Rockefeller Foundation announces a new $30 million Advance Market Commitment (AMC) to scale up pandemic testing needs and safely reopen schools, communities, and the economy.
-
RedHill Biopharma Announces Closing of $25 Million Bought Deal Offering
1/14/2021
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced underwritten offering of 3,188,776 American Depositary Shares (ADSs) of the Company, at a price to the public of $7.84 per ADS
-
PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category
1/14/2021
- New category targets programs that support the transition from adolescence to adulthood - - Proposal submissions for 2021 STRIVE Awards are due March 15, 2021 -
-
TransEnterix Announces Closing of $31.25 Million Registered Direct Offering of Common Stock
1/14/2021
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced the closing of its previously announced registered direct offering of 25,000,000 shares of its common stock.
-
Viveve Announces Pricing of Upsized $24 Million Underwritten Public Offering
1/14/2021
Viveve Medical, Inc. ("Viveve") (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced the pricing of an upsized underwritten public offering of units for gross proceeds of approximately $24 Million (or $27.6 million if the underwriters exercise their option to purchase additional shares) prior to deducting underwriting discounts and commissions and offering expenses payable by Viveve.
-
Pfizer anticipates the initiative to invest up to half-a-billion dollars in small- to medium-sized companies developing clinical-stage assets aligned with Pfizer’s core areas of focus.
-
Sana Biotechnology has filed with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering to help support the company’s cell-based therapy discovery and development operations.
-
The two companies will work together to use dendritic cells to develop immune tolerance.
-
Major players in the biotech industry are moving full steam ahead in their 2021 operations goals despite the ongoing pandemic, with global pharmaceutical giant Takeda being no exception.
-
Cancer companies Delfi Diagnostics and Elucida Oncology announced Series A raises worth $144 million so far.
-
Asahi Kasei to Build a Second Plant for Ceolus™ Microcrystalline Cellulose
1/13/2021
Asahi Kasei's Specialty Solutions SBU will build a second plant for microcrystalline cellulose [1] (trade name Ceolus™) at its Mizushima Works in Kurashiki, Okayama, Japan.